Press Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
May 8, 2019
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced financial results for the quarter ended March 31, 2019, and provided a corporate update. First Quarter and Recent...
-
Apr 3, 2019
Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it has filed suit against Clarus Therapeutics, Inc....
-
Mar 27, 2019
Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced findings from the Ambulatory Blood Pressure Monitoring...
-
Mar 26, 2019
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today acceptance of their abstract for late-breaker presentation on LPCN 1144 clinical results as part of The...
-
Mar 21, 2019
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will provide a corporate overview and LPCN 1144's therapeutic...
-
Mar 14, 2019
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that it has been selected to present LPCN 1144 clinical results as part of ENDO 2019. The presentation will...
-
Mar 12, 2019
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on endocrine and metabolic disorders, today announced top-line results from the 16-week Liver Fat Imaging Study ("Liver Fat...
-
Mar 11, 2019
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that Morgan Brown, Executive Vice President and Chief Financial Officer, will provide a corporate overview to...
-
Mar 6, 2019
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced financial results for the year ended December 31, 2018. Fourth Quarter 2019 and Recent Corporate Highlights...
-
Feb 14, 2019
Lipocine Inc. (Nasdaq: LPCN), a specialty pharmaceutical company, today announced that the U.S. Food & Drug Administration ("FDA") indicated that the Phase 2 clinical study of LPCN 1144 in...